Eli Lilly and Company (BVL:LLY)
Peru
· Delayed Price · Currency is PEN · Price in USD 1,007.00
-56.50 (-5.31%)
At close: Dec 5, 2025
Revenue
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| Baqsimi Revenue | - | 29.10M |
Log In |
Log In |
Log In | Upgrade
|
| Basaglar Revenue | 657.70M | 676.90M |
Log In |
Log In |
Log In | Upgrade
|
| Glucagon Revenue | - | - |
Log In |
Log In |
Log In | Upgrade
|
| Humalog Revenue | 2.26B | 2.32B |
Log In |
Log In |
Log In | Upgrade
|
| Humulin Revenue | 805.30M | 917.10M |
Log In |
Log In |
Log In | Upgrade
|
| Jardiance Revenue | 3.86B | 3.34B |
Log In |
Log In |
Log In | Upgrade
|
| Mounjaro Revenue | 19.09B | 11.54B |
Log In |
Log In |
Log In | Upgrade
|
| Trajenta Revenue | 336.00M | 353.90M |
Log In |
Log In |
Log In | Upgrade
|
| Trulicity Revenue | 4.49B | 5.25B |
Log In |
Log In |
Log In | Upgrade
|
| Zepbound Revenue | 11.19B | 4.93B |
Log In |
Log In |
Log In | Upgrade
|
| Other Cardiometabolic Health Revenue | 150.80M | 187.90M |
Log In |
Log In |
Log In | Upgrade
|
| Cardiometabolic Health Revenue | 42.84B | 29.52B |
Log In |
Log In |
Log In | Upgrade
|
| Oncology Revenue | 9.32B | 8.75B |
Log In |
Log In |
Log In | Upgrade
|
| Immunology Revenue | 5.00B | 4.39B |
Log In |
Log In |
Log In | Upgrade
|
| Neuroscience Revenue | 1.32B | 1.47B |
Log In |
Log In |
Log In | Upgrade
|
| Other Product Revenue | 942.20M | 903.00M |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Other) | -11.19B | -4.93B |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Total) | 59.42B | 45.04B |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| US Revenue | 39.64B | 30.38B |
Log In |
Log In |
Log In | Upgrade
|
| Europe Revenue | 10.91B | 6.92B |
Log In |
Log In |
Log In | Upgrade
|
| Japan Revenue | 2.04B | 1.81B |
Log In |
Log In |
Log In | Upgrade
|
| China Revenue | 1.91B | 1.66B |
Log In |
Log In |
Log In | Upgrade
|
| Other Foreign Countries Revenue | 4.93B | 4.27B |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Other) | 100.00K | 100.00K |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Total) | 59.42B | 45.04B |
Log In |
Log In |
Log In | Upgrade
|
Key Performance Indicators
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2012 - 2019 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2012 - 2019 |
| Revenue Change due to Price | 5.00% |
Log In |
Log In |
Log In | Upgrade
|
| Revenue Change due to Volume | 27.00% |
Log In |
Log In |
Log In | Upgrade
|
| Revenue Change due to FX | - |
Log In |
Log In |
Log In | Upgrade
|